Aspira Pathlab & Diagnostics Ltd
Aftertrade Broking Pvt Ltd ("Manager to the Offer") has informed BSE regarding Intimation of Identified Date for the Proposed Open Offer of Aspira Pathlab & Diagnostics Ltd ('Target Company') ....
M&A
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 25 Mar 2026, 12:01 PM IST · BSE ID: 1128bf0c-6e61-4d31-b4ee-3f366db470ba
View Original BSE Filing (PDF)
💡
In Simple Terms
A group of five investors is offering to buy 26% of a diagnostic lab company from public shareholders at ₹55 per share.
🤖 AI Summary
- Open offer for 26,76,180 equity shares at ₹55 per share representing 26% of fully paid-up equity capital
- Acquirers: Arvind Karsandas Bhanushali, Deepali Arvind Bhanushali, Jay Arvind Bhanushali, Nikunj Velji Mange, Raj Arvind Bhanushali, and PAC Shraddha Nikunj Mange
- Identified date fixed as 27 March 2026 for determining eligible shareholders to receive Letter of Offer
- Manager to Open Offer: Aftertrade Broking Private Limited; Public announcement dated 26 September 2025
🔢 Key Numbers — exact figures from BSE filing, not rounded
Offer shares quantity
26,76,180 equity shares
Offer price per share
₹55
Percentage of equity capital
26%
Identified date
27 March 2026
🏢 How This Affects the Company
Open offer triggers potential change in ownership and control. Upon completion, acquirers will hold controlling stake, shifting management and strategic direction of the pathology business.
Share transfer will move 26% equity ownership to acquirers. Estimated transaction size based on 26,76,180 shares at ₹55 per share is ₹147.19 crore. Balance sheet capitalization will remain unchanged but ownership composition shifts.
Management and operational continuity dependent on acquirers' intentions post-acquisition. Public shareholders face dilution but no direct operational disruption during offer period.
👥 What This Means For Shareholders
✅
Action Required
Public shareholders holding shares as on 27 March 2026 should verify holdings are credited in demat account to receive and participate in open offer.
👤
Who Is Affected
Public shareholders of Aspira Pathlab holding equity shares as on identified date 27 March 2026 are eligible to tender shares in the open offer at ₹55 per share for up to 26,76,180 shares (26% of capital).
🔍
Management Signal
Acquirers intend to acquire controlling stake; acquisition structure with five individuals plus PAC suggests coordinated investor group seeking operational control.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Letter of Offer dispatch to eligible shareholders—verify receipt within 30 days post identified date
Acceptance rate and closing date announcement—track public shareholder participation in open offer
Completion filing (Reg 31A(10))—confirms acquisition closed and new promoter reclassification effective
MEDIUM RISK
Open offer creates ownership transition risk. Public shareholders face potential delisting or restructuring post-acquisition if acquirers increase stake beyond 26%.
💡 Investor Takeaway
Open offer for 26% of Aspira Pathlab at ₹55 per share (₹147.19 crore transaction value) identified date now 27 March 2026. Public shareholders must verify holdings to receive Letter of Offer. Acquisition structure and post-completion strategy remain undisclosed.
⚖️ Strengths & Concerns
✅ Positives
- Clear identified date (27 March 2026) established per SEBI Reg 18(2), ensuring transparent shareholder identification process
- Formal public announcement (26 September 2025) and detailed statement (6 October 2025) published for shareholder awareness
⚠️ Concerns
- Filing is procedural status update only—no disclosure of offer rationale, strategic intent, or post-acquisition business plans
- 26% stake acquisition leaves 74% dispersed; unclear if acquirers hold existing stake or this represents first entry